Your browser doesn't support javascript.
loading
Exploring a Novel Approach to Spare Classic Chemotherapy in HER2-Low, ER-Positive Breast Cancer Based on Trastuzumab Deruxtecan Combined with Endocrine Therapy.
Scafuri, Luca; Buonerba, Carlo; Di Lauro, Vincenzo; Tortora, Vincenzo; Cascella, Marco; Liguori, Luigi; Sciarra, Antonella; Sabbatino, Francesco; Diana, Anna; Marra, Antonio; Tarantino, Paolo; Trapani, Dario; Giuliano, Mario; Arpino, Grazia; Curigliano, Giuseppe; Di Lorenzo, Giuseppe.
Afiliación
  • Scafuri L; Oncology Unit, "Andrea Tortora" Hospital, ASL Salerno, Pagani, Italy. lucaluca@hotmail.it.
  • Buonerba C; Associazione O.R.A. ETS-Oncology Research Assistance, Salerno, Italy. lucaluca@hotmail.it.
  • Di Lauro V; Oncology Unit, "Andrea Tortora" Hospital, ASL Salerno, Pagani, Italy.
  • Tortora V; Associazione O.R.A. ETS-Oncology Research Assistance, Salerno, Italy.
  • Cascella M; Department of Breast & Thoracic Oncology, Division of Breast Medical Oncology, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Naples, Italy.
  • Liguori L; S.C. Oncologia, ASL Vercelli, Vercelli, Italy.
  • Sciarra A; Anesthesia and Pain Medicine, Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, Via S. Allende, 84081, Baronissi, Italy.
  • Sabbatino F; Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
  • Diana A; Department of Experimental Medicine, University of Campania 'Luigi Vanvitelli', Naples, NA, Italy.
  • Marra A; Oncology Unit, Department of Medicine, Surgery and Dentistry, University of Salerno, 84081, Baronissi, Salerno, Italy.
  • Tarantino P; Medical Oncology Unit, Ospedale del Mare, Naples, Italy.
  • Trapani D; European Institute of Oncology-IRCCS, Milan, Italy.
  • Giuliano M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Arpino G; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.
  • Curigliano G; Harvard Medical School, Boston, MA, USA.
  • Di Lorenzo G; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
Oncol Ther ; 12(3): 363-373, 2024 Sep.
Article en En | MEDLINE | ID: mdl-38941050
ABSTRACT

BACKGROUND:

Breast cancer presents diverse molecular subtypes affecting treatment strategies. Human epidermal growth factor receptor 2 (HER2)-low, hormone receptor-positive (HR+) breast cancer poses a challenge due to limited targeted therapies. Current neoadjuvant treatment primarily utilizes chemotherapy, with conflicting results regarding efficacy in patients with HER2-low breast cancer. Trastuzumab deruxtecan (T-DXd) shows promise in HER2-low metastatic disease, and preliminary evidence suggests synergy with endocrine therapy.

OBJECTIVE:

This editorial explores the hypothesis that neoadjuvant T-DXd with or without endocrine therapy offers efficacy in the clinical management of HR+/HER2-low breast cancer.

METHODS:

We propose a phase II study with two treatment arms T-DXd + letrozole and T-DXd alone. The primary endpoint is the radiological complete response rate. Secondary endpoints include pathological complete response rate, safety, event-free survival, and overall survival. Exploratory analyses will compare the arms to identify potential for optimizing treatment efficacy and minimizing side effects.

CONCLUSIONS:

This study design allows for initial assessment of T-DXd with or without endocrine therapy in the treatment of HER2-low breast cancer. The findings may pave the way for personalized treatment strategies and inform future research, potentially leading to a chemotherapy-sparing approach.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Oncol Ther Año: 2024 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Nueva Zelanda
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Oncol Ther Año: 2024 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Nueva Zelanda